The combination of trastuzumab and cytotoxic chemotherapy, mainly taxanes, has been shown to significantly improve outcomes for women with HER2-overexpressing breast cancer, improving time to disease progression and overall survival [6]. The gene discussed is ERBB2; the disease is breast carcinoma.